Eli Lilly plans to slash prices of some older insulins, expand cost cap Lawmakers and patient advocates have been pressuring drugmakers to take action on soaring drug prices. Chicago Sun-Times · Mar 1, 2023
Eli Lilly is capping customers’ insulin costs at $35 Eli Lilly & Co. is capping out-of-pocket costs for insulin at $35 a month, following a public plea from President Joe Biden for lower prices of the diabetes treatment for all Americans. Tribune News Service · Mar 1, 2023
Eli Lily caps the cost of insulin at $35 a month, bringing relief to millions of Americans. As insulin prices have soared, this manufacturer announces it will reduce costs by 70%. Fortune · Mar 1, 2023
Eli Lilly cuts the price of insulin, capping drug at $35 per month out-of-pocket The moves announced Wednesday promise critical relief to some people with diabetes who can face annual costs of more than $1,000 for insulin they need in order to live. WEKU · Mar 1, 2023
Under pressure, Eli Lilly cuts insulin prices 70% Drugmaker Eli Lilly says it's cutting the price of one insulin to below 1990s levels. Axios · Mar 1, 2023
Lilly plans to slash some insulin prices, expand cost cap Eli Lilly will cut prices for some older insulins later this year and immediately expand a cap on costs insured patients pay when they fill prescriptions The Independent UK · Mar 1, 2023
The ‘next Ozempic’ became a social media sensation. Then everything changed When Mounjaro came on the market, TikTok went wild. People with obesity ordered the drug in droves thanks to a coupon that allowed them to access it for just $25 a month. Then the coupon went away, leaving destruction in its wake — and obese patients warring with diabetics. Emily… The Independent UK · Mar 1, 2023
The ‘next Ozempic’ became a social media sensation. Then everything changed When Mounjaro came on the market, TikTok went wild. People with obesity ordered the drug in droves thanks to a coupon that allowed them to access it for just $25 a month. Then the coupon went away, leaving destruction in its wake — and obese patients warring with diabetics. Emily… The Independent UK · Feb 28, 2023
The ‘next Ozempic’ became a social media sensation. Then everything changed When Mounjaro came on the market, TikTok went wild. People with obesity ordered the drug in droves thanks to a coupon that allowed them to access it for just $25 a month. Then the coupon went away, leaving destruction in its wake — and obese patients warring with diabetics. Emily… The Independent UK · Feb 27, 2023
The ‘next Ozempic’ became a social media sensation. Then everything changed When Mounjaro came on the market, TikTok went wild. People with obesity ordered the drug in droves thanks to a coupon that allowed them to access it for just $25 a month. Then the coupon went away, leaving destruction in its wake — and obese patients warring with diabetics. Emily… The Independent UK · Feb 26, 2023
The ‘next Ozempic’ became a social media sensation. Then everything changed When Mounjaro came on the market, TikTok went wild. People with obesity ordered the drug in droves thanks to a coupon that allowed them to access it for just $25 a month. Then the coupon went away, leaving destruction in its wake — and obese patients warring with diabetics. Emily… The Independent UK · Feb 25, 2023
The 5 Safest Stocks You Can Buy in 2023 The stock market might remain volatile in the near term amid the still-alarmingly high inflation and the anticipated continuation of rate hikes. Therefore, fundamentally strong Eli Lilly (LLY), Novartis (NVS), Comcast (CMCSA), HCA Healthcare (HCA), and Myers Industries (MYE), which pay steady dividends, might be safe buys now. Read more. StockNews.com · Feb 24, 2023
The ‘next Ozempic’ became a social media sensation. Then everything changed When Mounjaro came on the market, TikTok went wild. People with obesity ordered the drug in droves thanks to a coupon that allowed them to access it for just $25 a month. Then the coupon went away, leaving destruction in its wake — and obese patients warring with diabetics. Emily… The Independent UK · Feb 24, 2023
The ‘next Ozempic’ became a social media sensation. Then everything changed When Mounjaro came on the market, TikTok went wild. People with obesity ordered the drug in droves thanks to a coupon that allowed them to access it for just $25 a month. Then the coupon went away, leaving destruction in its wake — and obese patients warring with diabetics. Emily… The Independent UK · Feb 22, 2023
The Independent UK · Jan 20, 2023 Lilly shares slip as FDA seeks more Alzheimer's drug data Eli Lilly shares slipped Friday morning after regulators said they need to see more data on the company’s application for a quick approval of its potential Alzheimer’s disease treatment
Tribune News Service · Jan 16, 2023 Obesity treatments catch drugmakers’ eyes as sales seen soaring Three years ago, drugmakers and laboratories around the world responded to the pandemic with Covid-19 vaccines. Now that the urgency has faded, they’re collectively turning attention to an older pandemic: obesity.
Tribune News Service · Dec 31, 2022 A TikTok trend sold out Ozempic, leaving people with diabetes dizzy, scared For more than a month, Shane Anthony, a 57-year-old auto mechanic, hasn’t been able to get his diabetes medication.
StockNews.com · Dec 22, 2022 3 Large-Cap Stocks to Add to Your Portfolio Now The Fed’s aggressive stance on inflation has weighed heavily on the stock market this year. As large-cap stocks usually can weather challenging economic conditions, sound large-cap stocks Eli Lilly (LLY), Agilent Technologies (A), and Fortinet (FTNT) might be wise additions to your portfolio. Keep reading.
ABC News · Nov 12, 2022 Pharmaceutical giant Eli Lilly & Co apologises after fake Twitter account says insulin is free as Elon Musk rolls back verification The incident is among a wave of impersonations that prompted Twitter to make its relaunched premium service unavailable.
Fortune · Nov 11, 2022 No, insulin is not free: Eli Lilly is the latest high-profile casualty of Elon Musk’s Twitter verification mess Eli Lilly shares fell after pranksters using Twitter Blue impersonated it and made a surprising claim—and this might be just the beginning.
The Independent UK · Nov 11, 2022 Pharmaceutical companies’ stocks dive after verified imposter Twitter account claims ‘insulin is free’ Insulin producers Eli Lilly, Novo Nordisk and Sanofi all reported losses during Friday’s trading
The Guardian - US · Nov 6, 2022 These companies claim to support abortion rights. They are backing anti-abortion Republicans An analysis of major companies’ donations, including Meta and Amazon, reveals donations to candidates calling for banning the procedure
Tribune News Service · Oct 19, 2022 New generation of weight loss medications offer promise — but at a price Excitement is building about a new generation of drugs that tout the ability to help adults with excess weight shed more pounds than older drugs on the market.
StockNews.com · Oct 18, 2022 3 Names It Wouldn’t Hurt to Stock up On Despite the Fed’s continued hawkish stance, the September inflation report came in hotter than expected, raising the possibility of another aggressive interest rate hike in November. However, it could be smart to keep investing in quality stocks to benefit from their rebound. We think Microsoft (MSFT), Eli Lilly (LLY), and…
Benzinga · Sep 27, 2022 Elon Musk Twitter Case Deposition Delayed, FTX US Goes Shopping, Spotify's Analyst Sees Audiobooks Immaterial: Top Financial Media Stories Tuesday, Sept. 27 Bloomberg